Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...

While gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of pipeline and marketed gMG drugs.

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and ...

PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL ...

AZ has already made it clear its focus is on investing in the US market – which accounts for 30% of its sales – and started ...

(Alliance News) - AstraZeneca PLC on Thursday said phase 3 data regarding its investigational inhibitor gefurulimab met its primary endpoint in myasthenia gravis activities of daily living.

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

Despite growing competition and an expanding array of differentiated dosing profiles designed to enhance patient convenience, retention on first-line biologics remains exceptionally high at 90%, ...

Results from the global PREVAIL Phase 3 trial showed that gefurulimab met its primary endpoint, demonstrating a statistically significant and ...

Oral therapy showed dose-dependent increases in progranulin protein levels in both plasma and cerebrospinal fluid; >95% mean increase in progranulin levels in CSF, compared to baseline; favorable ...

Here are the top FTSE 100 Index shares to watch next week, including BT Group, BP, IAG, Marks and Spencer (MKS) and AstraZeneca ...